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Abstract
MicroRNAs (miRNAs) are small non-coding RNAs that regulate
gene expression post-transcriptionally. They are involved in key bio-
logical processes and then may play a major role in the development
of human diseases including cancer, in particular their involvement in
breast cancer metastasis has been confirmed. Recently, the authors of
ref.([27] have found that miR-429 may have a role in the inhibition of
breast cancer metastasis and have identified its target gene CRKL as
a potential candidate. In this paper, by using systems biology tools we
have shown that CRKL is involved in positive regulation of ERK1/2
signaling pathway and contribute to the regulation of LYN through a
topological generalization of feed forward loop
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1 Introduction
MicroRNAs are an evolutionarily conserved class of small (about 22
nucleotides) non-coding RNAs that negatively regulate gene expres-
sion post transcriptionally by base-pairing to the 3’UTR of target
mRNAs leading to repression of protein production or mRNA degra-
dation. Each miRNA can regulate the expression of hundreds of genes
and a single transcript can be targeted by multiple miRNAs. (For a
recent introduction see for example [15]
Since their discovery in 1993 [11] there have been increasing evi-
dences that they are involved in important biological processes. In-
deed, in normal cells, miRNAs control normal rates of cellular growth,
proliferation, differentiation and apoptosis. Involvement of miRNAs
in diverse cellular events indicates that dysregulated expression and
function may lead to development of differnt deseases including can-
cer. A potential role of miRNAs in the development and progression
of cancer has been suggested by some observations early in the history
of miRNAs. one of these observations is that tumor cell lines and ma-
lignant tumors were found to have widespread deregulation of miRNA
expression compared to normal tissues [22]. Thus, tumor formation
may be a consequence of a reduction of a tumor suppressor miRNA or
overexpression of an oncogene miRNA .Examples of tumor suppres-
sor miRNAs are let-7 family, miR-29, miR-34 and miR -15, and of
oncogene miRNAs are miR-17-92, miR-155 and miR-221.
miRNA involvement has been observed in almost every type of
cancer including breast cancer [18, 25]. Breast cancer is the most
common type of cancer among women. However, the majority of deths
from breast cancer are not due to the primary tumor itself, but are
the result of metastasis. Breast cancer metastasis is a very complex
process that comprises a series of sequential steps and involves several
processes [19].
Several miRNAs have been found to be involved in the breast can-
cer metastasis. For instance, an up-regulated miR-21 down-regulates
the PTEN which inhibits cell migration, spreading and focal adhe-
sion. miR-10b which is an important miRNA is involved in causing
epithelial-mesenchymal transition (EMT).
MicroRNAs which are involved in activating the epithelial differ-
entiation in breast cancer cells include the members of miR-200 family
[22, 18].The miRNA miR-429 belongs to this family that contains also
miR-200a, miR-200b, miR-200c and miR-141. These five members are
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found in two clusters. In human, miR-200a, miR-200b and miR-429
are located on chromosome 1, while miR-200c and miR-141 are on
chromosome 12. They are highly enriched in epithelial tissues [8].
There are growing evidences that miR-200 microRNAs are in-
volved in cancer metastasis. Indeed, they have been shown to in-
hibit epithelial-mesenchymal transition (EMT) which is the initiating
step of metastasis by maintaining the epithelial phenotype through
direct targeting of transcriptional repressors of E-cadherin, ZEB1 and
ZEB2 [17, 24, 16]. There is also evidence that the miR-200 family
is up-regulated in distal breast metastasis indicating that these miR-
NAs are important for colonization of metastatic breast cancer cells
through induction of mesenchymal to epithelial transition [2].
It has been shown that miR-429 (with other two miRNAs) can
be a potential biomarker of early human non-small cell lung cancer
(NSCLC) [30]. It has also been demonstrated that the expression of
miR-429 is often upregulated in NSCLC compared with normal lung
tissues. It has been found that overexpression of miR-429 promotes
cell proliferation, migration and invasion [10].
miR-429 was also found to be involved in pancreatic cancer stem
cells [9], colorectal cancer[23], ovarian cancer [3] and also in breast
cancer. Recently a study carried out by Zhi-Bin Ye and coworkers
revealed that decreased expression of miR-429 are probably involved
in negatively regulating bone metastasis of breast cancer cells [27]. On
the other hand, its overexpression remarkably suppressed invasion.
By combining the in silico analysis of miR-429 targets and global
transcriptional profile they have identified CRKL as a potential target
that was probably a fundamental node in controlling bone metastasis
of breast cancer.
Crk-like (CRKL) is an adapter protein that has crucial roles in mul-
tiple biological processes, including cell proliferation, adhesion, and
migration. It has been found to be overexpressed in many malignant
tumors and plays crucial roles in tumor progression. It contributes to
pancreatic cancer cell proliferation and invasion through ERK signal-
ing [4], and promotes lung cancer cell invasion through ERK-MMP9
pathway [13]. CrkL plays also a regulatory role in the SDF-1-induced
Erk1/2 and PI3K/Akt pathways and further managed the invasion
and migration of breast cancer cells [12]. It has been shown that
overexpression of CRKL correlated with progression and malignant
proliferation of human breast cancers [29].
The purpose of this paper is perform a systems biology study to
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elucidate the role of CRKL in breast cancer metastasis and find out
some of the biological processes in which it is involved. To achieve
this goal we use systems biology tools.
2 Materials and methods
We begin by downloading the list of target genes of miR-429 from the
DIANA-TarBase v7,0 database that catalogues published experimen-
tally validated miRNA gene interactions [6]. With the list of genes we
have just obtained we use IntAct to find curated interactions 1 .
To visualize the resulting network we use the cytoscape 3,2,0, an
open source software platform for visualizing complex networks and
integrating these with any type of attribute data. [20]. In order to
identify groups of genes that share a similar function we use the clus-
terMaker, a Cytoscape application developed at UCSF that allows the
user to easily create and visualize topological clusters using a great va-
riety of methodologies, here we use the GLay Community Clustering
algorithm.
In order to determine which Gene Ontology (GO) terms are signif-
icantly overrepresented in this set of genes we use the BiNGO Plugin
of Cytoscape [14].
3 Results and discussion
By uploading the list of target genes onto cytoscape and after filtering
by taxonomy identifier and choosing the human case the resulting
network consists of 5172 nodes and 18177 edges. Then, by applying
the clusterMaker cytoscape plugin we obtaing the result shown in
figure figure 1
In our study we focus on the signaling process because of its impor-
tant role in mediating each stage of tumour metastasis [26]. We apply
the BINGO plugin to the cluster containing CRKL which consists of
700 nodes and 1192 edges. From the network view of the result of GO
analysis by BINGO we see that all the branches going out from the
1IntAct is one of the largest available repositories for curated molecular interactions
data, storing PPIs as well as interactions involving other molecules. It is hosted by the
European Bioinformatics Institute. IntAct has evolved into a multisource curation plat-
form and many other databases curate into IntAct and make their data available through
it [21].
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Figure 1: Figure 1: The result of the Glay Community Clustering Algorithm
applied to the targetome of miR-429
regulation of signaling process term converge on the positive regula-
tion of ERK 1 and ERK 2 cascade term which has a p-value equal to
4.5× 10−10. The parent term is the positive regulation of MAPKKK
cascade with a p-value equal to 2× 10−16.
The extracellular signal-regulated kinase ERK 1/2 mitogen acti-
vated protein MAP kinase module is known as a conserved signaling
pathway that plays a major role in the control of cell proliferation, sur-
vival and differentiation. Its involvement in cancer has been proved
by convincing evidences. In vitro studies of cancer cell lines and in
vivo findings from animal models have highlighted the role of ERK
1/2 signaling in cell survival, motility, invasiveness and angiogenesis.
Accumulating evidences suggest that the ERK1/2 signaling pathway
also contributes to the increased motility, invasiveness and dissemina-
tion of tumor cells. ERK 1/2 may then contribute to every step of the
metastatic process [26].
On another side, by performing a network motif search using visant,
the analysis tool for biological networks and pathways2 we found that
CRKL is involved in many feed forward loops, some of them contain
LYN a member of Src family kinases.
2http://visant.bu.edu/
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CRKL −− > KHDRBS1− >> LY N (1)
CRKL −− > GAB1− >> LY N (2)
CRKL −− > ABI1− >> LY N (3)
CRKL −− > EGFR− >> LY N (4)
CRKL −− > BCAR1− >> LYN (5)
CRKL −− > MAP4K1− >> LY N (6)
CRKL −− > SHC1− >> LY N (7)
CRKL −− > SYK− >> LY N (8)
CRKL −− > TYK2− >> LY N (9)
CRKL −− > CBL− >> LY N (10)
CRKL −− > KIT− >> LY N (11)
CRKL −− > BLNK− >> LY N (12)
Figure 2: Figure 2: A multi-y generalization of feed forward network motif
where CRKL is the input and LYN is the output
Indeed, Src family kinases (SFK) such as Lyn mediate signal trans-
duction and are involved in the regulation of tumor cell proliferation,
adhesion, motility, and invasion, and contribute to tumor progression,
metastasis, and angiogenesis . As a member of SFK, Lyn was found to
play a role in inhibiting tumor growth and metastasis in Ewing’s sar-
coma [5]. It was also shown to be a mediator of epithelial-mesenchymal
transition and target of dasatinib in breast cancer [28]. The functions
of the Lyn tyrosine kinase in health and disease have been reviewed
in [7].
6
According to figure 2 CRKL and LYN are involved in a topolog-
ical generalization of the feed forward loop (FFL) which consists in
its basic form of only three nodes: an input (X), moderator (Y) and
output (Z) node. It is encountered with some of its topological gener-
alizations as a key functional component in gene transcription, signal
transduction and neural networks [1]. However, the present case rep-
resents a multi-y generalization of the FFL which needs further study,
in particular the determination of the sign of the different edges (acti-
vation or repression). We can suspect a combinatorial control of LYN
by CRKL together with the other genes.
We have thus shown the involvement of CRKL in the positive
regulation of ERK1/2 signaling pathway. We have also found that it
may contribute to the regulation of LYN through a generalized FFL.
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